Nothing Special   »   [go: up one dir, main page]

AU2002225219A1 - Diagnosis and treatment of multiple sclerosis - Google Patents

Diagnosis and treatment of multiple sclerosis

Info

Publication number
AU2002225219A1
AU2002225219A1 AU2002225219A AU2002225219A AU2002225219A1 AU 2002225219 A1 AU2002225219 A1 AU 2002225219A1 AU 2002225219 A AU2002225219 A AU 2002225219A AU 2002225219 A AU2002225219 A AU 2002225219A AU 2002225219 A1 AU2002225219 A1 AU 2002225219A1
Authority
AU
Australia
Prior art keywords
diagnosis
treatment
multiple sclerosis
sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002225219A
Inventor
Herath Mudiyanselage Athula Chandrasiri Herath
Rajesh Bhikhu Parekh
Christian Rohlff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Glycosciences UK Ltd
Original Assignee
Oxford Glycosciences UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences UK Ltd filed Critical Oxford Glycosciences UK Ltd
Publication of AU2002225219A1 publication Critical patent/AU2002225219A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
AU2002225219A 2001-01-26 2002-01-25 Diagnosis and treatment of multiple sclerosis Abandoned AU2002225219A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26440401P 2001-01-26 2001-01-26
US60/264,404 2001-01-26
US33164701P 2001-11-20 2001-11-20
US60/331,647 2001-11-20
PCT/GB2002/000330 WO2002059604A2 (en) 2001-01-26 2002-01-25 Diagnosis and treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
AU2002225219A1 true AU2002225219A1 (en) 2002-08-06

Family

ID=26950517

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002225219A Abandoned AU2002225219A1 (en) 2001-01-26 2002-01-25 Diagnosis and treatment of multiple sclerosis

Country Status (4)

Country Link
EP (1) EP1354199A2 (en)
JP (1) JP2004532386A (en)
AU (1) AU2002225219A1 (en)
WO (1) WO2002059604A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7015004B2 (en) 2001-11-23 2006-03-21 Syn X Pharma, Inc. Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
US20030113808A1 (en) * 2001-12-13 2003-06-19 George Jackowski Apolipoprotein biopolymer markers predictive of alzheimers disease
AU2004222345A1 (en) * 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
EP2517718B1 (en) 2003-05-15 2016-03-02 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ES2730728T3 (en) 2004-05-12 2019-11-12 Brigham & Womens Hospital Inc Use of gelsolin to treat infections
US20050266467A1 (en) * 2004-05-19 2005-12-01 Ppd Biomarker Discovery Sciences, Llc Biomarkers for multiple sclerosis and methods of use thereof
WO2006005583A2 (en) * 2004-07-12 2006-01-19 Geneprot Inc. Secreted polypeptide species involved in multiple sclerosis
WO2006069739A2 (en) * 2004-12-27 2006-07-06 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
WO2006074787A2 (en) * 2004-12-27 2006-07-20 Geneprot Inc. Polypeptide species useful for the treatment of neurological disorders
US20070017809A1 (en) * 2005-07-21 2007-01-25 Power3 Medical Products, Inc. Assay for ALS and ALS-like disorders
AU2007227613A1 (en) * 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP2002258B1 (en) * 2006-03-15 2017-09-27 The Brigham and Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
JPWO2009020058A1 (en) * 2007-08-03 2010-11-04 学校法人慶應義塾 Drug delivery system for demyelinating lesions and biochemical markers of demyelinating lesions
EP2522753B1 (en) * 2007-08-13 2014-04-02 Baxter International Inc. IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease
AU2013276992C1 (en) * 2007-08-13 2016-08-11 Takeda Pharmaceutical Company Limited IVIG Modulations of Chemokines for Treatment of Multiple Sclerosis, Alzheimer's Disease, and Parkinson's Disease
CA2749985C (en) 2008-01-25 2020-07-07 The General Hospital Corporation Therapeutic use of gelsolin in chronic renal failure
JP5856843B2 (en) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ,インコーポレイテッド Pharmaceutical composition using diketopiperazine
WO2010005387A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab New method and biomarkers for the diagnosis of multiple sclerosis
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
EP3101426B1 (en) 2010-12-16 2019-05-15 National Institute of Advanced Industrial Science And Technology Alpha2-macroglobulin from cerebrospinal fluid as an index marker for neuromyelitis optica
CN103841987B (en) 2011-10-10 2015-06-17 安皮奥制药股份有限公司 Treatment of degenerative joint disease
BR112014007657A2 (en) 2011-10-10 2017-04-11 Ampio Pharmaceuticals Inc Implantable medical devices with improved immune tolerance and methods for production and implantation
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
ITMI20120865A1 (en) * 2012-05-18 2013-11-19 Antonio Bertolotto BIOMARCERS FOR PATHOLOGIES OF THE CENTRAL NERVOUS SYSTEM
SG10201707619RA (en) 2013-03-15 2017-10-30 Ampio Pharmaceuticals Inc Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
EP3183240A4 (en) 2014-08-18 2018-06-27 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
RU2694614C1 (en) * 2019-01-22 2019-07-17 Общество с ограниченной ответственностью "ВЕСТТРЭЙД ЛТД" (ООО "ВЕСТТРЭЙД ЛТД") Method of pathological process activity determining in patients with multiple sclerosis
WO2020172262A1 (en) * 2019-02-19 2020-08-27 James Janine Chromium composition and methods thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321160A1 (en) * 1998-02-13 1999-08-19 Oxford Glycosciences (Uk) Ltd. Methods and compositions for diagnosis of hepatoma

Also Published As

Publication number Publication date
JP2004532386A (en) 2004-10-21
EP1354199A2 (en) 2003-10-22
WO2002059604A2 (en) 2002-08-01
WO2002059604A8 (en) 2002-11-21
WO2002059604A3 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
AU2002225219A1 (en) Diagnosis and treatment of multiple sclerosis
AU2002323258A1 (en) Diagnosis and treatment of vascular disease
AU2002247004A1 (en) Methods of diagnosis and treatment of osteoporosis
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2002367535A1 (en) Diagnosis and treatment of vascular disease
AU2002259130A1 (en) Agents for treatment of hcv and methods of use
AU2003268295A1 (en) "diagnosis and treatment of infertility"
AU2002258728A1 (en) Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002326813A1 (en) Diagnosis and treatment of vascular disease
AU2002305151A1 (en) Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002253990A1 (en) Diagnosis and treatment of inflammation and hyperactive immune conditions
AU3760400A (en) Methods and reagents for the diagnosis and treatment of multiple sclerosis
AU2002341880A1 (en) Diagnosis and treatment of vascular disease
AU2002341604A1 (en) Diagnosis and treatment of vascular disease
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002360696A1 (en) Combination comprising anti-cd52 antibodies and other therapeutic agents for treatment for multiple sclerosis
EP1409734A4 (en) Diagnosis and treatment of cancer
GB2381272B (en) Diagnosis and treatment of atherosclerosis
AU2002210286A1 (en) Medicine intended for treatment of multiple sclerosis
AU2002249891A1 (en) Compounds and methods for the diagnosis and treatment of babesia infection
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2002319591A1 (en) Diagnosis and treatment of vascular disease
AU2002330649A1 (en) Diagnosis and therapy of conditions involving alms1

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase